NICE | pharmaphorum

Skip to main content

Tuesday 3 November 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

NICE

Articles

harvoni

NICE calls the shots on Harvoni – but NHS England eyeing pri...

Harvoni and rival hep C drugs look set for approval in England – but NHS England may have the last word on controlling costs, finds Andrew McConaghie.

News

NICE1

NICE to launch ‘Office for Market Access’

NICE is to establish a new Office for Market Access to help life sciences companies prepare for its cost effectiveness appraisals and improve their chances of gaining a 'yes'.

News

Kadcyla

Roche challenges NICE on Kadcyla and ignoring pricing deal

Row over breast cancer drug Kadcyla continues

Views & Analysis

NICE-logo_16-9

Who influences NICE technology appraisals?

In the world of pharmaceuticals everyone seems to have heard of the National Institute for Health and Care Excellence (NICE).

Views & Analysis

Social Network Social Media People Meeting Communication Concept

Pharma gets social: did digital opinion leaders shape NICE g...

Digital Opinion Leaders as activists in healthcare decision making.

Editor's Picks

UK budget includes £1bn biopharma investment package

HHS doubles down on controversial peptides plan

Lilly's triple G overpowers Ozempic in diabetes trial

UK puts £100m into "world-first" AI biosecurity facility

US gives $99m for Ebola jab project, as cases spread in Africa

Oncology

On the benefits of earlier oncological intervention, with Johnson & Johnson

On the benefits of earlier oncological intervention, with Jo...

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company